5-fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary
- 30 April 1988
- journal article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 24 (4), 765-768
- https://doi.org/10.1016/0277-5379(88)90312-4
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Mitomycin C-induced renal toxicity, a dose-dependent side effect?European Journal of Cancer and Clinical Oncology, 1987
- VAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary siteEuropean Journal of Cancer and Clinical Oncology, 1983
- Metastatic adenocarcinoma of unknown primary site: Analysis of 245 patients seen at the johns hopkins hospital from 1965-1979Medical and Pediatric Oncology, 1982
- 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreasCancer, 1980
- 5-Fluorouracil, Doxorubicin, and Mitomycin (FAM) Combination Chemotherapy for Advanced Gastric CancerAnnals of Internal Medicine, 1980
- Metastatic Adenocarcinomas of Unknown Primary SiteNew England Journal of Medicine, 1980
- Unknown primary adenocarcinoma: incidence of overinvestigation and natural history.BMJ, 1979
- 5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lungCancer, 1979
- Metastatic Carcinomas from Occult Primary TumorsAnnals of Surgery, 1977
- Treatment of the patient with adenocarcinoma of unknown originCancer, 1972